FOSTER CITY, Calif., March 12, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment ...

Co-founder Finny Kuruvilla manages the firm’s largest two funds — Eventide Gilead and Eventide Healthcare and Life Sciences — and remains the firm’s largest owner, though more than 20 of ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

Gilead markets several single-tablet regimens for HIV, and its next-generation products with better long-term safety profiles, led by Biktarvy, are boosting the company's market share.

The Handmaid's Tale season 6 will depict the greatest rebellion against Gilead yet. The season is poised to serve as the show ...

Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.

After hours: March 26 at 7:46:21 p.m. EDT Loading Chart for GILD ...

As of 13 March at 3:46:08 pm GMT-4. Market open.

After hours: 24 March at 7:55:37 pm GMT-4 Loading Chart for GILD ...

As of 21 March at 2:05:17 pm GMT-4. Market open.

$ 109.69 USD 1.80 1.67% ...

Competition page helps you compare Gilead Sciences Inc. with its sector peers on key parameters.